NPAA Takes Action Against 93 Drug Brands (India)
This article was originally published in PharmAsia News
Executive Summary
India's National Pharmaceutical Pricing Authority (NPAA) has instituted a serious crackdown on drug companies who promised to cut prices but have not done so. Previously, the pharmaceutical manufacturers made an agreement with the agency to reduce the price of 886 brands. Now, the NPAA has instituted fixed pricing for 37 brands. It is now also obligated the producers of 56 other brands to reimburse the government for the amount they overcharged. According to NPAA representatives, this is only the beginning. A survey of 12 of the countries largest cities found approximately half of the 574 samples were also guilty of overcharging. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.